# CVL006 Combination Therapy in Advanced Solid Tumors

> **NCT07157956** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Convalife (Shanghai) Co., Ltd.** · enrollment: 318 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** CVL006 combined with pemetrexed and carboplatin
- **DRUG:** CVL006 in combination with SKB264
- **DRUG:** CVL006 in combination with DS-8201
- **DRUG:** CVL006 in combination with Enfortumab Vedotin

## Key facts

- **NCT ID:** NCT07157956
- **Lead sponsor:** Convalife (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2028-08-12
- **Final completion:** 2028-12-30
- **Target enrollment:** 318 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07157956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07157956, "CVL006 Combination Therapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07157956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*